

Aaron S. Meyer

ameyer@ucla.edu
310-794-4821
<http://asmlab.org>

4121G Engineering V
Los Angeles, CA 90095

Education

Ph.D., Biological Engineering April 2014
Massachusetts Institute of Technology, Cambridge, MA
Thesis: Quantitative approaches to understanding signaling regulation of 3D cell migration

B.S., Bioengineering, magna cum laude June 2009
University of California, Los Angeles, CA

Research Experience

Assistant Professor 2017 – Present
Bioengineering Department, University of California, Los Angeles

- Assembling mechanistic model of FcγR engagement and activation sufficient to accurately predict *in vivo* IgG-driven effector function
- Further refining our understanding of TAM receptor activation response and role in targeted therapy and chemotherapy resistance

Principal Investigator & Research Fellow 2014 – 2017
Koch Cancer Institute, MIT, Cambridge, MA

- Developed systems cancer cell resistance model allowing predictive precision therapy selection
- Refined models of TAM receptor activation for optimal immunotherapeutic targeting

Graduate Researcher in the labs of Douglas Lauffenburger & Frank Gertler 2009 – 2014
Department of Biological Engineering & Koch Cancer Institute, MIT, Cambridge, MA

- Identified similarities in migration response between dimensionalities, suggesting relevant migration assays for invasive disease
- Studied transactivation of TAM receptors and its role in promoting motility response
- Developed systems models of TAM signaling, unifying conflicting observations regarding the receptors in normal biology and suggesting new methods of intervention to modulate activity

Undergraduate Researcher in the lab of Daniel Kamei 2006 – 2009
Department of Bioengineering, University of California, Los Angeles, CA

- Investigated biomarker purification using novel aqueous micellar systems
- Extended a previous statistical mechanics model to nucleic acid partitioning
- Designed and executed experiments to analyze the partitioning of surfactant systems
- Developed assays for quantifying the concentration of charged and uncharged surfactants

Summer Intern, Bioprocess Development Division 2008
Schering-Plough Corporation, Watchung, NJ

- Developed a novel method for high-throughput batch culture within deep-welled microtiter plates
- Investigated the social behavior of nonproducing impurities within monoclonal cultures

- Provided statistical basis for process-based confidence in monoclonality

Refereed Publications

- Robinett, R.A., N. Guan, A. Lux, M. Biburger, F. Nimmerjahn, **A.S. Meyer**. "Dissecting FcγR Regulation Through a Multivalent Binding Model." *Cell Systems*. 2018; In press.
- Muffat, J., Y. Li, A. Omer, A. Durbin, I. Bosch, G. Bakiasi, E. Richards, **A.S. Meyer**, L. Gehrke, R. Jaenisch. "Human iPS-derived Glial Cells and Neural Progenitors Display Divergent Responses to Zika and Dengue Infections." *Proc. Natl. Acad. Sci. U.S.A.* 2018; In press.
- Schwartz, A.D., L.E. Barney, L.E. Jansen, T.V. Nguyen, C.L. Hall, **A.S. Meyer**, S.R. Peyton. "A Biomaterial Screening Approach to Reveal Microenvironmental Mechanisms of Drug Resistance." *Integrative Biology*. 2017 Nov 14; 9: 912–924.
- Zweemer, A.J.M., C.B. French, J. Mesfin, S. Gordonov, **A.S. Meyer**, D.A. Lauffenburger. "Apoptotic Cell Bodies Elicit Gas6-Mediated Migration Of AXL-Expressing Tumor Cells." *Molecular Cancer Research*. 2017 Sept 18.
- Archer, T.C., E.J. Fertig, S.J.C. Gosline, M. Hafner, S.K. Hughes, B.A. Joughin, **A.S. Meyer**¹, S.P. Piccolo, A. Shajahan-Haq. "Systems Approaches to Cancer Biology." *Cancer Research*. 2016 Nov 18; 76 (23); 1–4.
- Manole, S., E.J. Richards, **A.S. Meyer**. "JNK pathway activation modulates acquired resistance to EGFR/HER2 targeted therapies." *Cancer Research*. 2016 Sept 15; 76 (18): 5219–5228.
- McConnell, R.E., J.E. Van Veen, M. Vidaki, A.V. Kwiatkowski, **A.S. Meyer**, D.A. Lauffenburger, F.B. Gertler. "A Requirement for Filopodia Extension Towards Slit During Robo-Mediated Axon Repulsion." *Journal of Cell Biology*. 2016 Apr 18; 213 (2): 261.
- Miller, M.A., M.J. Oudin, R.J. Sullivan, D.T. Frederick, **A.S. Meyer**, S. Wang, H. Im, J. Tadros, L.G. Griffith, H. Lee, R. Weissleder, K.T. Flaherty, F.B. Gertler, D.A. Lauffenburger. "Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance." *Cancer Discovery*. 2016 Apr; 6:331-333.
- Miller, M.A., M. Moss, G. Powell, R. Petrovich, L. Edwards, **A.S. Meyer**, L.G. Griffith, D.A. Lauffenburger. "Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain." *Scientific Reports*. 2015 Oct 19; 5:15150.
- Meyer**², **A.S.**, A.J.M. Zweemer, D.A. Lauffenburger². "The AXL receptor is a sensor of ligand spatial heterogeneity." *Cell Systems*. 2015 Nov 29; 1(1):25-36.
- Riquelme, D.N., **A.S. Meyer**, M. Barzik, A. Keating, F.B. Gertler. "Selectivity in subunit composition of Ena/VASP tetramers." *Biosci. Rep.* 2015 Jul 28;35(5). pii: e00246.
- Meyer, A.S.**, M.A. Miller, F.B. Gertler, D.A. Lauffenburger. "The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells." *Science Signaling*. 2013 Aug 6; 6(287):ra66.
- Miller³, M.A., **A.S. Meyer**³, M. Beste, Z. Lasisi, S. Reddy, K. Jeng, C.-H. Chen, J. Han, K. Isaacson, L.G. Griffith, D.A. Lauffenburger. "ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling." *Proc. Natl. Acad. Sci. U.S.A.* 2013 May 28; 110(22):E2074-83.
- Meyer, A.S.**, S.K. Hughes-Alford, J.E. Kay, A. Castillo, A. Wells, F.B. Gertler, D.A. Lauffenburger. "2D protrusion

¹Corresponding author.

²Co-corresponding authors.

³Equally contributing authors.

but not motility predicts growth factor-induced cancer cell migration in 3D collagen." *Journal of Cell Biology*. 2012 Jun 11; 197(6):721-9.

Kim, H.D., **A.S. Meyer**, J.P. Wagner, S.K. Alford, A. Wells, F.B. Gertler, D.A. Lauffenburger. "Signaling network state predicts Twist-mediated effects on breast cell migration across diverse growth factor contexts." *Mol. Cell. Proteomics*. 2011 Nov;10(11):M111.008433.

Meyer, A.S., R.G. Condon, G. Keil, N. Jhaveri, Z. Liu, Y.-S. Tsao. "Fluorinert, an oxygen carrier, improves cell culture performance in deep square 96-well plates by facilitating oxygen transfer." *Biotechnol. Prog.* 2012 Jan; 28(1):171-8.

Mashayekhi, F., **A.S. Meyer**, S.A. Shiigi, V. Nguyen, D.T. Kamei. "Concentration of mammalian genomic DNA using two-phase aqueous micellar systems." *Biotechnol. Bioeng.* 2009 Apr 15; 102(6):1613-23.

Research Support & Awards

NCI Cancer Systems Biology Consortium U01 U01-CA215709 – "Precision Lung Cancer Therapy Design through Multiplexed Adapter Measurement"	2017 – 2022
Fellowship Grant Terri Brodeur Breast Cancer Foundation "Decoding the Role of TAM Receptors <i>In Vivo</i> Using More Specific and Potent Inhibitors"	2017 – 2019
Ten to Watch, Amgen Scholars Foundation	2016
AMIGOS Program Award Jayne Koskinas Ted Giovanis Foundation and Breast Cancer Research Foundation "Understanding the Role of Cell Plasticity in Mediating Drug Resistance"	2016 – 2020
Frontier Research Program Initiator Award Koch Institute for Integrative Cancer Research "Multiplexed Tools for Probing Chemokine Receptor Activation State in Breast Cancer"	2015
NIH Director's Early Independence Award DP5-OD019815 – "Adapter-Layer RTK Signaling: Basic Understanding & Targeted Drug Resistance"	2014 – 2019
Highlighted by the NIH director's office.	
Siebel Scholar, Class of 2014	2013
Whitaker Fellowship Massachusetts Institute of Technology	2013
Repligen Fellowship in Cancer Research Koch Institute for Integrative Cancer Research	2012
Frontier Research Program Initiator Award Koch Institute for Integrative Cancer Research "Global Growth Factor Reprogramming and Invasion By AXL Expression And Shedding In Breast Carcinoma"	2011
Breast Cancer Research Predoctoral Fellowship Department of Defense W81XWH-11-1-0088 – "Molecular Regulatory Network Dysregulation in Breast Cancer Cell Migration & Invasion"	2010 – 2014
Graduate Research Fellowship National Science Foundation	2009 – 2014

Momenta Presidential Fellowship 2009
Massachusetts Institute of Technology

Teaching Experience

Instructor, Machine Learning & Data-Driven Modeling in Bioengineering 2018
UCLA, Department of Bioengineering

- Designed project-based course tailored to the background of students in the program

Faculty of the Citizen Science Program July 2015 – January 2016
Bard College, Citizen Science Program, Annandale-on-Hudson, NY

- Led a short course introducing students to the natural sciences and scientific method

Teaching Assistant, Thermodynamics of Biomolecular Systems 2010
MIT, Department of Biological Engineering, Cambridge, MA

- Taught at weekly discussion sections, office hours, and individual appointments
- Helped write and graded problem sets and exam questions

Conference & Invited Presentations

Univ. of Calif., Riverside, Department of Bioengineering, Invited Departmental Seminar April 2018
Meyer, A.S. "Dissecting FcyR Regulation Through a Multivalent Binding Model."

Univ. of Bergen, Centre for Cancer Biomarkers, Invited Speaker March 2018
Meyer, A.S. "Engineering more precise and potent TAM-targeted therapies."

Univ. of Calif., Los Angeles, Department of Bioengineering, Invited Departmental Seminar October 2017
Meyer, A.S. "Dissecting FcyR Regulation Through a Multivalent Binding Model."

Univ. of Calif., Los Angeles, Broad Stem Cell Research Center, Invited Speaker October 2017
Meyer, A.S. "Engineering more precise and potent TAM-targeted therapies."

Momenta Pharmaceuticals, Invited Oral Presentation April 2017
Robinett, R.A., N. Guan, **A.S. Meyer**. "Dissecting FcyR Regulation Through a Multivalent Binding Model."

Univ. of Pennsylvania, Department of Bioengineering, Invited Departmental Speaker March 2017
Meyer, A.S. "Engineering more precise and potent TAM-targeted therapies."

Univ. of Calif., Los Angeles, Department of Bioengineering, Invited Departmental Speaker March 2017
Meyer, A.S. "Engineering more precise and potent TAM-targeted therapies."

Moffitt Cancer Center, Invited Speaker January 2017
Meyer, A.S. "Engineering more precise and potent TAM-targeted therapies."

Biomedical Engineering Society Annual Meeting, Selected Oral Presentation October 2016
Manole, S., E.J. Richards, **A.S. Meyer**. "JNK pathway activation modulates acquired resistance to EGFR/HER2 targeted therapies."

MD Anderson Cancer Center, Dept. of Systems Biology, Invited Departmental Speaker September 2016
Richards, E.J., A. Zweemer, **A.S. Meyer**. "Engineering more precise and potent TAM-targeted therapies."

MD Anderson Cancer Center, Future of Science Symposium, Invited Oral Presentation September 2016
Manole, S., **A.S. Meyer**. "Toward precision therapy: Identifying molecular commonalities among RTK bypass resistance mechanisms."

- FASEB Protein Kinase Signaling Network Regulation*, Invited Oral Presentation July 2016
 Richards, E.J., A. Zweemer, **A.S. Meyer**. "Engineering more precise and potent TAM-targeted therapies."
- Univ. of Calif., Irvine, Center for Complex Biological Systems*, Invited Departmental Speaker May 2016
 Manole, S., E.J. Richards, **A.S. Meyer**. "Data-driven design of targeted therapies and immunotherapies for cancer."
- Systems Approaches to Cancer Biology*, NCI Invited Oral Presentation April 2016
 Manole, S., E.J. Richards, **A.S. Meyer**. "Looking across resistance mechanisms to identify molecular commonalities and precision therapy approaches."
- Applied Mathematics in Germinating Oncology Solutions Workshop*, NCI Invited Participant March 2016
- NIH Common Fund High-Risk High-Reward Symposium* December 2015
 Manole, S., E.J. Richards, **A.S. Meyer**. "Conserved RTK-intrinsic signaling consequences result in distinct bypass resistance capacity dependent upon pathway dependencies."
- Harvard Medical School, Brugge lab*, Invited Oral Presentation November 2015
 Manole, S., E.J. Richards, **A.S. Meyer**. "Conserved RTK-intrinsic signaling consequences result in distinct bypass resistance capacity dependent upon pathway dependencies."
- Biomedical Engineering Society Annual Meeting* October 2015
 Manole, S., **A.S. Meyer**. "Conserved RTK-intrinsic signaling consequences result in distinct bypass resistance capacity dependent upon pathway dependencies."
- ICBP Principal Investigators Meeting* May 2015
 Manole, S., **A.S. Meyer**. "Conserved RTK-intrinsic signaling consequences result in distinct bypass resistance capacity dependent upon pathway dependencies."
- NIH Common Fund High-Risk High-Reward Symposium* December 2014
Meyer, A.S.. "Adapter-Layer Integration of RTK Signaling: Basic Understanding and Application to Prediction of Targeted Drug Resistance."
- Biomedical Engineering Society Annual Meeting*, Selected Oral Presentation October 2014
Meyer, A.S., C.A. Riley, D.A. Lauffenburger. "AXL Is a Spatial Ligand Differentiation Sensor."
- Interdisciplinary Signaling Workshop*, Selected Oral Presentation July 2014
Meyer, A.S., C.A. Riley, D.A. Lauffenburger. "AXL Is a Spatial Ligand Differentiation Sensor."
- ICBP Principal Investigators Meeting* May 2014
Meyer, A.S., C.A. Riley, D.A. Lauffenburger. "AXL is a spatial ligand differentiation sensor."
- AACR Molecular Targets and Cancer Therapeutics* October 2013
Meyer, A.S., F.B. Gertler, D.A. Lauffenburger. "AXL amplifies EGFR signaling and drives resistance in triple negative breast carcinoma cells."
- Merrimack Pharmaceuticals*, Invited Oral Presentation October 2013
Meyer, A.S., C.A. Riley, D.A. Lauffenburger. "AXL is a spatial ligand differentiation sensor."
- ICBP Principal Investigators Meeting* May 2013
Meyer, A.S., F.B. Gertler, D.A. Lauffenburger. "AXL amplifies EGFR signaling and drives resistance in triple negative breast carcinoma cells."
- Merrimack Pharmaceuticals*, Invited Oral Presentation January 2013
Meyer, A.S., F.B. Gertler, D.A. Lauffenburger. "AXL amplifies EGFR signaling and drives resistance in triple negative breast carcinoma cells."

Professional Service

<i>Interviewee</i> , Prescriber Magazine	2017
<i>Ad Hoc Reviewer</i> , WIREs Systems Biology and Medicine	2017
<i>Ad Hoc Remote Reviewer</i> , Irish Research Council	2017
<i>Co-Chair</i> , Association of Early Career Cancer Systems Biologists	2017 – Present
<i>Ad Hoc Reviewer</i> , Cell Reports	2017
<i>Graduate Research Fellowship Program Review Panelist</i> , National Science Foundation	2016 – 2017
<i>Meeting Organizer & Member</i> , Association of Early Career Cancer Systems Biologists	2015 – 2016
<i>Ad Hoc Reviewer</i> , Drug Discovery Today	2016
<i>Ad Hoc Reviewer</i> , Molecular Cell	2015
<i>Member</i> , Biomedical Engineering Society	2010 – Present
<i>Coordinator</i> , MIT Biological Engineering Graduate Student Board	2010 – 2013
<i>Ad Hoc Reviewer</i> , Oncogene	2013
<i>Ad Hoc Reviewer</i> , Nature	2013
<i>Member</i> , MIT Biological Engineering Retreat Organizing Committee	2010 – 2012
<i>Ad Hoc Reviewer</i> , J. Cell Biol.	2011 – 2012

Patents/Disclosures

Bae, S.Y., **A.S. Meyer**. "Small Molecule Competitive Inhibitors Of Phosphatidylserine-TAMR Ligand Interaction." Disclosure filed, 2018.

Richards, E.J., S. Manole, **A.S. Meyer**. "Modulating JNK activation to impede lung & breast cancer RTK inhibitor bypass resistance." Disclosure filed, 2016.

Miller, M.A., M.J. Oudin, **A.S. Meyer**, L.G. Griffith, F.B. Gertler, D.A. Lauffenburger. "Methods of Reducing Kinase Inhibitor Resistance." US patent application 14/690,001, 2015.

Thesis Committee Membership

Daniel Bradbury, Bioengineering
Advisor: Daniel Kamei

Giovanni Valdez, Bioengineering
Advisor: Grace Xiao